Margriet Kwint

Outcome of treatment of synchronous oligometastases 61 3 Table 4: Univariate and multivariate Cox regression analysis for Progression Free Survival (PFS) and Overall Survival (OS) . HR = Hazard Ratio, EGFR= epidermal growth factor receptor, NOS= not otherwise specified. WHO PS: World Healthcare Organization Performance Score. GTV = Gross Tumor Volume. * For GTV total volume the patients were ranked in 3 equal groups. Variable HR (OS) univariate P-value (OS) univariate HR (OS) multivariate P-value (OS) multivariate HR (PFS) univariate P-value (PFS) univariate HR (PFS) multivariate P-value (PFS) multivariate Sex Male 1.000 1.000 Female 0.710 0.305 1.031 0.904 Age < 57 1.000 1.000 57-65 0.568 0.180 0.993 0.984 65< 1.242 0.572 1.271 0.454 WHO WHO PS 0 1.000 1.000 1.000 WHO PS 1-2 0.667 0.018 2.512 0.010 0.812 0.105 Pathology Adenoca 1.000 1.000 1.000 Squamousca 3.207 0.014 3.630 0.007 2.042 0.087 NOS 1.109 0.812 0.974 0.952 0.866 0.667 Neuro-en- dodrinee 1.437 0.559 0.908 0.879 1.334 0.585 EGFR (ref EGFR+) 0.744 EGFR+ 1.356 0.558 1.285 0.512 EGFR - 2.148 0.135 1.093 0.822 Thoracic stage Stage I&II 0.976 0.943 1.051 0.851 Stage III 1.000 1.000 T-stadium T0-1 1.000 1.000 1.000 T2 1.947 0.146 2.070 0.037 2.070 0.037 T3 1.097 0.868 0.871 0.750 0.871 0.750 T4 2.509 0.084 2.753 0.012 2.753 0.012 N-stage N0 1.000 1.000 N+ 1.309 0.483 1.141 0.334 GTV total volume* GTV-small 1.000 1.000 GTV-interme- diate 1.746 0.259 1.317 0.450 GTV-large 2.416 0.069 1.381 0.379 Total metastasis number 1 1.000 1.000 >1 0.684 0.603 0.975 0.954